The U.S.
Unfractionated Heparin Market, by Source (Porcine and Bovine), by Injection
Type (IV Injection and Subcutaneous Injection), and by Disease Indication
(Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary
Embolism & Arterial Embolism), was valued at US$ 335.4 million in 2018 and
is expected to exhibit a CAGR of 4.5% over the forecast period (2019 – 2027),
as highlighted in a new report published by Coherent Market Insights.
Increasing prevalence of
thromboembolic diseases, owing to the rising number of obese and older
population in U.S. is expected to drive growth of the U.S. unfractionated
heparin market over the forecast period. For instance, according to the
Circulation Research Journal, a journal of the American Heart Association
(AHA), in 2016, in the U.S., study estimates showed that age-stratified
incidence was 143 per 100,000 among people of age 40 to 49 years, 200 per
100,000 among people of age 50 to 59 years, 391 per 100,000 among people of age
60 to 69 years, 727 per 100,000 among people of age 70 to 79 years, and 1,134
per 100,000 among people of age ≥80 years.
Major players are focusing on
acquisitions to expand their product portfolio and presence in the market,
which is expected to drive the market growth over the forecast period. For
instance, in July 2016, Nichi-Iko Pharmaceutical Co., Ltd acquired Sagent
Pharmaceuticals, Inc., a U.S.-based manufacturer of pharmaceutical injectable,
valued at US$ 736 million. This acquisition enhanced Nichi-Iko’s presence in
the U.S. market to commercialize its biosimilar product portfolio.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3187
Browse 12 Market Data Tables and
10 Figures spread through 82 Pages and in-depth TOC on ‘U.S. Unfractionated
Heparin Market’, by Source (Porcine and Bovine), by Injection Type (IV
Injection and Subcutaneous Injection), and by Disease Indication (Venous
Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism
& Arterial Embolism) - Global Forecast to 2027.
The U.S. unfractionated heparin
market is expected to exhibit growth over the forecast period, owing to
increasing prevalence of thromboembolic diseases. For instance, according to
the Circulation Research Journal, a journal of the American Heart Association,
in 2016, the study reported that the incidence of venous thromboembolism (VTE)
is higher as age increases in the U.S.
Moreover, favorable regulatory
framework is also offering lucrative opportunity for growth of the market. For
instance, in September 2019, the U.S. Food and Drug Administration (FDA)
directed that all forms of imported heparin are subjected to compliance testing,
in order to reduce risk of complication such as heparin induced
thrombocytopenia and deaths associated with imported heparin.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/us-unfractionated-heparin-market-3187
Key Takeaways of the U.S.
Unfractionated Heparin Market:
The global U.S. unfractionated
heparin market is expected to exhibit a CAGR of 4.5% over the forecast period,
owing to increasing cases of thromboembolism in the U.S. and acquisition
strategies by players in the U.S. unfractionated heparin market
Among source, porcine segment
held dominant position in the U.S. unfractionated heparin market in 2018, owing
to the U.S. Food and Drug Administration (FDA) approval for sources used for
manufacturing of heparin. For instance, the only commercially available source
in U.S. for the heparin production is porcine, derived from porcine intestinal
mucosa.
Among injection type, IV
injection segment held dominant position in the U.S. unfractionated heparin
market in 2018, owing to rising mergers & acquisitions by market players.
For instance, in September 2016, Baxter International Inc. acquired Claris
Injectable, an India-based generic injectable pharmaceutical company. This
acquisition helped Baxter to increase the production of injectable such as
anesthesia and analgesics, anti-infective, renal and critical care products.
Among disease indication, venous
thromboembolism segment held dominant position in the U.S. unfractionated
heparin market in 2018, owing to rising cases of thromboembolism. According to
the data and statistics published by the National Center on Birth Defects and Developmental
Disabilities, a part of Centers for Disease Control and Prevention in March
2019, venous thromboembolism (VTE) is the foremost cause of preventable
hospital death in the U.S. Around 5.0% to 8.0% of the U.S. population has one
of the several genetic risk factors. It is also known as inherited
thrombophilias, wherein a genetic defect can be identified that increases the
risk for thrombosis.
Companies operating in the global
U.S. unfractionated heparin market include Pfizer, Inc., Sagent Pharmaceuticals,
Inc., B. Braun Melsungen AG, Baxter International Inc., and Bayer AG
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3187
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment